Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer

OBJECTIVE: To evaluate the combination of pembrolizumab, cisplatin and gemcitabine in recurrent platinum-resistant ovarian cancer. METHODS: Patients received six cycles of chemotherapy with gemcitabine and cisplatin on day 1 and day 8 of a 21-day treatment cycle. Pembrolizumab was administered on da...

Descripción completa

Detalles Bibliográficos
Autores principales: Walsh, Christine S., Kamrava, Mitchell, Rogatko, Andre, Kim, Sungjin, Li, Andrew, Cass, Ilana, Karlan, Beth, Rimel, Bobbie J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174738/
https://www.ncbi.nlm.nih.gov/pubmed/34081738
http://dx.doi.org/10.1371/journal.pone.0252665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174738/
https://www.ncbi.nlm.nih.gov/pubmed/34081738
http://dx.doi.org/10.1371/journal.pone.0252665

Ejemplares similares